AMRI turns up its revenue guidance after a $174M buyout

Former Teva exec William Marth is the new CEO of AMRI
AMRI CEO William Marth

AMRI ($AMRI) is brightening its expectations for 2015 after closing its latest buyout, counting on its manufacturing division to keep revenue rolling.

The Albany, NY, company now expects full-year sales to come in between $386 million and $400 million, a 56% increase over 2014 at midpoint. In May, AMRI forecast $335 million to $370 million in contract revenue, a roughly 40% average jump.

AMRI's optimism is a reaction to the integration of Gadea Pharmaceutical, a Spanish contractor that manufactures complex active ingredients for pharma companies. AMRI bought the company for $174 million in cash and stock over the summer, extending a string of manufacturing-focusing acquisitions.

"Gadea brought us over 90 technically complex API programs, greatly enhancing our commercial portfolio and opportunities for expanded business," CEO William Marth said in a statement.

AMRI's gradual shift toward large-scale manufacturing has been paying off on the balance sheet. The company posted a net profit for the first time in 12 months last quarter, reaping the benefits of a years-long transition away from drug discovery.

- read the statement

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.